Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 20NETWORK 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Methylprednisolone Acetate × Clear all
NCT06209606 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Oncotherapeutics

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03110822 2023-11-01

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Oncotherapeutics

Phase 1 Recruiting
134 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡